An Open-Label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary.

Trial Profile

An Open-Label Randomized Phase II Trial of Belinostat (PXD101) in Combination With Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Previously Untreated Carcinoma of Unknown Primary.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Belinostat (Primary) ; Belinostat (Primary) ; Carboplatin; Paclitaxel
  • Indications Cancer; Carcinoma; Solid tumours
  • Focus Therapeutic Use
  • Sponsors TopoTarget
  • Most Recent Events

    • 28 Aug 2012 Results will be presented at major oncology meetings in 2013, according to a TopoTarget media release.
    • 28 Aug 2012 Additional analyses of time to treatment failure were reported in a TopoTarget media release.
    • 29 Jun 2012 Top-line safety and efficacy data were published, according to a TopoTarget media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top